Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 16/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 7/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25288956 | 0.98 | PTK6 (0.48) | PTK6BRAFLCKAURKBTTK | |
| SCHEMBL25238570 | 0.95 | PTK6 (0.49) | PTK6BRAFLCKAURKBTTK | |
| SCHEMBL25288598 | 0.94 | PTK6 (0.45) | PTK6BRAFLCKAURKBTTK | |
| SCHEMBL25238489 | 0.93 | PTK6 (0.45) | PTK6BRAFLCKAURKBTTK | |
| SCHEMBL25244327 | 0.93 | PTK6 (0.45) | PTK6BRAFLCKAURKBTTK | |
| Hydrochloric Acid SCHEMBL25283479 | 0.93 | PTK6 (0.45) | PTK6BRAFLCKAURKBTTK | |
| SCHEMBL25288384 | 0.92 | PTK6 (0.42) | PTK6BRAFLCKAURKB | |
| SCHEMBL25241377 | 0.92 | PTK6 (0.42) | PTK6BRAFLCKAURKB | |
| SCHEMBL25237809 | 0.92 | PTK6 (0.47) | PTK6BRAFLCKAURKBTTK | |
| SCHEMBL25243453 | 0.92 | PTK6 (0.46) | PTK6BRAFLCKAURKBTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | claimed |
| CN-115485279-A | Antibacterial 8-phenylamino-3- (pyrazol-4-yl) imidazo [1,2-a ] pyrazine derivatives | 豪夫迈·罗氏有限公司 | 2022-12-16 | — | — | CN | claimed |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| CN-115485279-A | Antibacterial 8-phenylamino-3- (pyrazol-4-yl) imidazo [1,2-a ] pyrazine derivatives | 豪夫迈·罗氏有限公司 | 2022-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IKZF3, INTS9, CYP2C9 | PTK6 1140/4885BRAF 789/4885LCK 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.